tetano
Editor, Senior Moderator
Front Immunol
. 2020 Aug 28;11:2086.
doi: 10.3389/fimmu.2020.02086. eCollection 2020.
COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis
Markus A Schramm[SUP] 1 [/SUP], Nils Venhoff[SUP] 1 [/SUP], Dirk Wagner[SUP] 2 [/SUP], Jens Thiel[SUP] 1 [/SUP], Daniela Huzly[SUP] 3 [/SUP], Nils Craig-Mueller[SUP] 1 [/SUP], Marcus Panning[SUP] 3 [/SUP], Hartmut Hengel[SUP] 3 [/SUP], Winfried V Kern[SUP] 2 [/SUP], Reinhard E Voll[SUP] 1 [/SUP]
Affiliations
Abstract
Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).
Keywords: COVID-19; EGPA; SARS-CoV-2; cyclophosphamide; eosinophilic granulomatosis with polyangiitis; immunosuppression; rituximab; vasculitis.
. 2020 Aug 28;11:2086.
doi: 10.3389/fimmu.2020.02086. eCollection 2020.
COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis
Markus A Schramm[SUP] 1 [/SUP], Nils Venhoff[SUP] 1 [/SUP], Dirk Wagner[SUP] 2 [/SUP], Jens Thiel[SUP] 1 [/SUP], Daniela Huzly[SUP] 3 [/SUP], Nils Craig-Mueller[SUP] 1 [/SUP], Marcus Panning[SUP] 3 [/SUP], Hartmut Hengel[SUP] 3 [/SUP], Winfried V Kern[SUP] 2 [/SUP], Reinhard E Voll[SUP] 1 [/SUP]
Affiliations
- PMID: 32983161
- PMCID: PMC7484740
- DOI: 10.3389/fimmu.2020.02086
Abstract
Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).
Keywords: COVID-19; EGPA; SARS-CoV-2; cyclophosphamide; eosinophilic granulomatosis with polyangiitis; immunosuppression; rituximab; vasculitis.